A phase I/II dose schedule finding study of ch14.18/CHO continuous infusion combined with subcutaneous Aldesleukin (IL-2) in patients with primary refractory or relapsed Neuroblastoma
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2018
At a glance
- Drugs Dinutuximab beta (Primary) ; Aldesleukin; Isotretinoin
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 30 May 2018 According to an Apeiron Biologics media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
- 05 Apr 2018 Planned number of patients changed to 444.
- 07 Jun 2016 Interim results (n=124) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology